CaverStem Revenue. It has begun!
That's a serious answer too.
Accounts receivable on Dec 31, 2017: $4,801. Accounts receivable on Sept 30, 2018: $14,000.
292% increase in accounts receivable? From what? Well, apparently they have succeeded in commercializing their patented CaverStem procedure and they even told us that they held back on revenue for Q3 to make sure everything was positioned the best for patients, docs and CMTH. Q4 will show that throttled back revenue and this is just the beginning.
Clinics are going to be, and many ALREADY ARE, cranking out treatments WORLDWIDE and when they're in full swing, revenue is going to bust loose.
Don't worry with the OS, revenues will cure what ails and market cap will absolutely reset to make this PPS trash a thing of the past.
If $CELZ has a market cap of $500M and 2B in OS, it's worth 25 cents. If it's $500M market cap and 1B OS, then its 50 cents. If it gets fairly valued for CaverStem, FemCelz, StemSpine and AminoStem...not to mention the other patents pending...then what Market Cap would it have? $1B? $10B? $20B? If it takes another Billion in OS to get this thing zooming with insane revenue, so be it. At $20B market cap and 2 Billion OS, the stock is worth $10 per share. $10.00 PER SHARE!!!!!!
Some biotech companies TODAY have OS of 5 BILLION and PPS of $45.00.
IT DOES NOT MATTER THE OS IF THE COMPANY IS VALUABLE. Bottom line? DO YOU THINK CMTH is VALUE-ABLE? CaverStem seems to be showing us that it is in real time. I certainly think CMTH is value-able and thus I hold for the returns that I sincerely expect in the not distant future.
All posts my opinions only. NOT INVESTMENT ADVICE. Do your own due diligence.
-- Narrow is the way and few are those who find it. --
